MAFLD and risk of CKD

Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018

“…16 Besides, a recent study conducted by Sun et al investigated the relationship between MAFLD and CKD based on NHANES 1988-1994, and revealed that MAFLD could identify CKD better than NAFLD. 17 Hence, MAFLD could give physicians more chance to intervene in the disease earlier. However, this study by Sun et al was conducted with out-of-date data.…”

Artificial intelligence in prediction of non‐alcoholic fatty liver disease and fibrosis

“…Recently, a group of expert hepatologists proposed to rename the condition as metabolic dysfunction‐associated fatty liver disease (MAFLD) and require the inclusion of metabolic risk factors in its diagnosis 22 . A handful of studies discussed the superiority of MAFLD over NAFLD in terms of diagnosis and prognosis 23–26 . In a population study from our group, we found that the prevalence of MAFLD and NAFLD was similar despite the slightly different definitions, whereas the new MAFLD definition may reduce the incidence of new‐onset disease from 13.8% to 10.4% in 3–5years 27 .…”

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

“…16 Of note, several recent studies have shown that the clinical characteristics, including renal function and fibrosis markers, of subjects with Non-MR NAFLD might be better than those of subjects with MAFLD. 17 However, another study showed that subjects with Non-MR NAFLD had a higher risk of CVD than those with neither NAFLD nor MAFLD, indicating the need for careful assessment and monitoring of this population. 16 In addition, more studies are needed to better elucidate the potential risk that can be the cause of future disease in 'lean' NAFLD without any metabolic dysregulation who was excluded from MAFLD criteria.…”

“…In contrast, a recent Chinese study using the NHANES III database showed that, the proportion of subjects with Non-MR NAFLD was higher (6.3% [n=793 of 12,571]) in these populations and that these subjects presented with favorable renal outcomes when compared to those with MAFLD (6.93% vs. 14.02% for albumin-to-creatinine ratio; mean 83.49 vs. 74.06 mL/min/1.73m 2 ; 6.43% vs. 20.28% for stage 3-5 chronic kidney disease; all p<0.05). 17 In another study from Japan, the proportion of Non-MR NAFLD was 15.3% and MAFLD without NAFLD was 24.2% among the subjects with FLD. 18 When they compared these groups they noted significant elevations in fatty liver index, APRI, NAFLD fibrosis score, and liver stiffness assessed using transient elastography, in MAFLD without NAFLD compared to Non-MR NAFLD (Table 4), which might indicate that subjects with Non-MR NAFLD might appear less severe than those of MAFLD in spite of the comparable long-term implications of these diseases.…”